The advent of next-generation sequencing (NGS) has transformed not only scientific research, but also clinical practice. As the next-generation sequencer has obtained CE certification in Europe and FDA certification in the United States, it is expected to be applied in more fields, including prenatal testing, genetic disease and tumor detection. Globally-renowned consulting firm Frost & Sullivan expects this approach to personalized medicine is driving steady growth in the next-generation sequencing market in Western Europe.
